# Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct03513029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03513029](<https://clinicaltrials.gov/study/NCT03513029>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03513029

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03513029. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-20 (actual); primary completion 2019-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03513029, source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)
- Started: 2018-01-20 (actual) (ClinicalTrials.gov record NCT03513029, source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)
- Primary completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT03513029, source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)
- Completion: 2019-12 (anticipated) (ClinicalTrials.gov record NCT03513029, source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)
- Countries: Czechia (ClinicalTrials.gov record NCT03513029, source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03513029-2018-05-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation
- Acronym: VITAL
- Condition: Paroxysmal Atrial Fibrillation
- Intervention (Device): VytronUS Ablation System
- Lead sponsor: VytronUS, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: d7a91fdb6df8f569be0e9f4632e31f8b416b7792165542cb52ec1a9d79c32731
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
